In BlueAllele Corp. v. Intellia Therapeutics, Inc., 2024 U.S. Dist. Lexis 222094 (D. Del. Dec. 9, 2024)1, the District of ...

EMERYVILLE, Calif. - Metagenomi, Inc. (NASDAQ: MGX), a biotechnology firm specializing in precision genetic medicines trading ...

MGX-001 in Hemophilia A Advances Towards US and Ex-US Regulatory Interactions in 2025NHP Proof-of-Concept Anticipated for Secreted Protein ...

The White House is honoring three Iowa State researchers for their work in artificial intelligence, genome editing and ...

Colossal, a leading biosciences company working to combat environmental dangers and revive extinct species, has reached a new ...

We are excited to welcome Eric to our Board of Directors,” said Brian C. Thomas, PhD, CEO and founder of Metagenomi. “His tremendous track record in the pharmaceutical industry as well as his ...

Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends lifespan by about 50 percent in a mouse model of the fatal ...

New research from the Center for Physical Genomics and Engineering uncovers how 3D genome structures generate cellular memories, paving the way for advances in medicine and longevity through cellular ...

CRISPR-Cas9 pioneer presented with National Medal of Technology and Innovation in White House awards ceremony China-born ...

The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...

A new technology, mvGPT, is capable of precisely editing genes, activating gene expression, and repressing genes all at the ...